REPL insider buying and SEC filings, explained
Replimune Group, Inc. · CIK 1737953
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$1.6M
Planned sales (10b5-1)
$274K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 17, 2026 | Sale | Emily Luisa Hill (CFO) sold 9,256 shares at about $14.28 ($132K). Holdings down 4% to 215,852 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 19, 2026 |
| Aug 10, 2026 | Sale | Sushil Patel (CEO and Director) sold 39,341 shares at $12.97 ($510K). Holdings down 5% to 708,151 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 12, 2026 |
| Aug 10, 2026 | Sale | Emily Luisa Hill (CFO) sold 11,448 shares at $12.97 ($148K). Holdings down 5% to 225,108 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 12, 2026 |
| Aug 10, 2026 | Sale | Konstantinos Xynos (Chief Medical Officer) sold 11,447 shares at $12.97 ($148K). Holdings down 5% to 224,215 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 12, 2026 |
| Aug 10, 2026 | Sale | Andrew Schwendenman (Chief Accounting Officer) sold 7,632 shares at $12.97 ($99K). Holdings down 7% to 99,425 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 12, 2026 |
| Aug 11, 2026 | Other purchase | Julian Baker (Director and 10% owner) bought 2,736,340 2026 $0.0001 Prefunded Warrants indirectly at $12.06 ($33.0M) in a public offering. New position of 2,609,946 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 5 other reporting owners. | SEC filing Filed Aug 11, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Christopher Sarchi (Chief Commercial Officer) sold 12,000 shares at about $9.24 ($111K), marked as a 10b5-1 plan trade. Holdings down 6% to 180,962 shares. | SEC filing Filed Jun 3, 2026 |
| May 18, 2026 | Sale | Konstantinos Xynos (Chief Medical Officer) sold 14,023 shares at about $5.08 ($71K). Holdings down 6% to 235,662 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 20, 2026 |
| May 18, 2026 | Sale | Andrew Schwendenman (Chief Accounting Officer) sold 7,894 shares at about $5.08 ($40K). Holdings down 7% to 107,057 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 20, 2026 |
| May 18, 2026 | Sale | Christopher Sarchi (Chief Commercial Officer) sold 8,626 shares at about $5.08 ($44K). Holdings down 4% to 192,962 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 20, 2026 |
| May 18, 2026 | Sale | Philip Astley-Sparke (Director) sold 17,657 shares at about $5.08 ($90K). Holdings down 1% to 1,412,414 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 20, 2026 |
| May 18, 2026 | Sale | Sushil Patel (CEO and Director) sold 37,324 shares at about $5.08 ($190K). Holdings down 5% to 747,492 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 20, 2026 |
| May 18, 2026 | Sale | Emily Luisa Hill (CFO) sold 7,812 shares at about $5.08 ($40K). Holdings down 3% to 236,556 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 20, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Christopher Sarchi (Chief Commercial Officer) sold 6,500 shares at about $8.01 ($52K), marked as a 10b5-1 plan trade. Holdings down 4% to 151,588 shares. | SEC filing Filed Apr 6, 2026 |
| Dec 2, 2025 | Planned (10b5-1) | Sushil Patel (CEO and Director) sold 10,000 shares at about $11.13 ($111K), marked as a 10b5-1 plan trade. Holdings down 3% to 333,576 shares. | SEC filing Filed Dec 4, 2025 |
| Nov 17, 2025 | Sale | Christopher Sarchi (Chief Commercial Officer) sold 5,208 shares at about $9.10 ($47K). Holdings down 4% to 123,088 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 19, 2025 |
| Nov 17, 2025 | Sale | Konstantinos Xynos (Chief Medical Officer) sold 7,248 shares at about $9.10 ($66K). Holdings down 5% to 139,685 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 19, 2025 |
25 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow REPL in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.